Galectin Therapeutics Inc. (GALT)
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?
Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
Clinical Progress Drives Galectin Shares Up Post-NAVIGATE Data
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating expenses post-trial, with a cash runway through mid-2026 after securing a $10M credit line. Belapectin demonstrated reductions in liver stiffness, fibrogenesis, and new varices, especially in high-risk patients, while maintaining a favorable safety profile.
Galectin Therapeutics: NAVIGATE Data Validates The Fibrosis Thesis
Galectin Therapeutics targets MASH cirrhosis with belapectin, addressing a highly unmet need with clear mechanistic rationale and promising clinical data. GALT's NAVIGATE trial showed belapectin's 2 mg/kg dose significantly reduced disease progression and varices in high-risk patients, with consistent biomarker improvements. Despite a constrained cash runway through mid-2026 and dose-response questions, GALT's insider support and strategic options provide financial flexibility ahead of regulatory milestones.
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know
Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?
On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks
The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Meet the 10 biggest megadonors in the 2024 election cycle so far
Following record-breaking fundraising by candidates in the 2022 midterms, this year's election cycle is shaping up to be another big one for megadonors.
